Keenan Smart
Psychiatry · Norman, OKNPI 1790120483
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.4% of the total. 2025 is the largest year on record at $1,397, 4.1 times the $344 reported in 2019. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $13.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$618
- Otsuka America Pharmaceutical, Inc.$502
- Johnson & Johnson$416
- Supernus Pharmaceuticals, Inc.$350
- Corium, LLC$337
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,47899%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 147 | $1,350 |
| AbbVie(2 entities) | 48 | $618 |
| Otsuka America Pharmaceutical, Inc. | 36 | $502 |
| Johnson & Johnson | 24 | $416 |
| Supernus Pharmaceuticals, Inc. | 19 | $350 |
| Corium, LLC | 18 | $337 |
| Tris Pharma Inc | 13 | $220 |
| Sunovion Pharmaceuticals Inc. | 23 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $173 |
| Alkermes, Inc. | 8 | $161 |
| Ironshore Pharmaceuticals Inc. | 8 | $161 |
| Adlon Therapeutics L.p. | 12 | $157 |
| Axsome Therapeutics, Inc. | 7 | $135 |
| Brainsway USA Inc | 1 | $124 |
| Noven Therapeutics, LLC | 5 | $86 |
| Collegium Pharmaceutical, Inc. | 4 | $85 |
| Lundbeck LLC | 3 | $59 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Shire North American Group Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Rhodes Pharmaceuticals L.p. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Indivior Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$111
How this compares
$5,527 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $959 |
| Duloxetine Hcl | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Norman
- Julia IrwinNorman$16K
- Richard HartmanNorman$15K
- Vivian HasbrookNorman$12K
- Uzma ZaidiNorman$11K
- Jack GrayNorman$9K
- Joseph RippergerNorman$6K
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.